April W Armstrong Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

5/2024	Brodalumab: 5-Year US Pharmacovigilance Report.
3/2024	Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
2/2024	Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation.
2/2024	Tips, Trends, and Truths: A Study of Psoriasis Treatment Content on TikTok.
1/2024	Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.
1/2024	Shared decision-making in psoriasis care: Evaluation of how patients' perception of clinicians' delivery of care changes by age and sex.
12/2023	Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
12/2023	Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
12/2023	Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States.
12/2023	Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

April W Armstrong Research Topics

Disease

119	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2024 - 03/2011
20	Psoriatic Arthritis 02/2024 - 10/2011
14	Atopic Dermatitis (Atopic Eczema) 12/2023 - 01/2012
11	Acne Vulgaris 03/2024 - 03/2011
11	Wounds and Injuries (Trauma) 01/2022 - 09/2013
9	Inflammation (Inflammations) 03/2024 - 07/2011
8	Neoplasms (Cancer) 05/2024 - 01/2012
7	Cicatrix (Scar) 01/2022 - 03/2015
6	Pruritus (Itching) 03/2024 - 01/2020
6	Infections 03/2024 - 01/2012
6	Eczema 11/2023 - 02/2015
5	Pain (Aches) 03/2024 - 03/2015
4	COVID-19 01/2023 - 10/2020
3	Folliculitis (Sycosis) 03/2024 - 01/2021
3	Hidradenitis Suppurativa 03/2024 - 08/2016
3	Body Weight (Weight, Body) 01/2023 - 10/2015
3	Insulin Resistance 01/2020 - 08/2013
3	Skin Neoplasms (Skin Cancer) 06/2014 - 05/2011
2	Hyperlipidemias (Hyperlipidemia) 11/2023 - 03/2011
2	Sarcoidosis (Schaumann Disease) 01/2023 - 01/2019
2	Overweight 01/2023 - 01/2018
2	Weight Loss (Weight Reduction) 12/2022 - 01/2018
2	Actinic Keratosis 10/2021 - 12/2014
2	Arthritis (Polyarthritis) 06/2021 - 02/2021
2	Communicable Diseases (Infectious Diseases) 01/2021 - 12/2020
2	Necrosis 11/2017 - 03/2014
2	Candidiasis (Moniliasis) 08/2016 - 10/2015
2	Melanoma (Melanoma, Malignant) 10/2014 - 01/2012
2	Hypertension (High Blood Pressure) 01/2014 - 03/2011
2	Rheumatoid Arthritis 01/2014 - 01/2014
2	Myocardial Infarction 09/2013 - 05/2013

Drug/Important Bio-Agent (IBA)

20	Adalimumab (Humira)FDA Link 11/2023 - 01/2012
14	Immunoglobulin A (IgA)IBA 11/2023 - 02/2015
13	apremilastIBA 03/2024 - 03/2014
13	guselkumabIBA 02/2023 - 03/2017
11	Interleukin-17 (Interleukin 17)IBA 01/2023 - 03/2014
11	secukinumabIBA 01/2023 - 03/2014
9	deucravacitinibIBA 03/2024 - 01/2023
9	Tumor Necrosis Factor InhibitorsIBA 01/2024 - 05/2013
9	Biomarkers (Surrogate Marker)IBA 12/2023 - 01/2018
9	Interleukin-23 (Interleukin 23)IBA 12/2023 - 12/2019
9	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 10/2013
8	Etanercept (Enbrel)FDA Link 03/2022 - 01/2012
7	Ustekinumab (CNTO 1275)FDA Link 01/2024 - 01/2012
7	InterleukinsIBA 11/2023 - 10/2014
7	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2023 - 09/2013
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 05/2013
7	Infliximab (Remicade)FDA Link 01/2019 - 01/2012
6	Monoclonal AntibodiesIBA 02/2024 - 08/2013
5	brodalumabIBA 05/2024 - 03/2014
5	CytokinesIBA 03/2024 - 08/2016
5	TYK2 Kinase (Tyrosine Kinase 2)IBA 03/2024 - 01/2023
5	tapinarofIBA 12/2023 - 01/2021
5	Interleukin-12 (IL 12)IBA 10/2023 - 07/2015
5	calcipotriene (calcipotriol)FDA LinkGeneric 09/2023 - 08/2019
4	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 12/2023 - 12/2021
4	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 09/2023 - 08/2019
4	ixekizumabIBA 03/2022 - 03/2014
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2017
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2016 - 01/2014
3	Interleukin-13IBA 03/2024 - 01/2020
3	Phosphodiesterase 4 InhibitorsIBA 10/2023 - 05/2020
3	Vitamin D FDA LinkGeneric 08/2023 - 01/2018
3	Isotretinoin (Accutane)FDA LinkGeneric 05/2021 - 03/2011
3	tofacitinibIBA 06/2020 - 01/2014
3	AntibodiesIBA 01/2019 - 01/2012
3	Antirheumatic Agents (DMARD)IBA 03/2014 - 01/2014
2	lebrikizumabIBA 02/2024 - 01/2020
2	VaccinesIBA 02/2024 - 10/2022
2	SDMIBA 01/2024 - 11/2023
2	abrocitinibIBA 12/2023 - 11/2023
2	Janus KinasesIBA 12/2023 - 01/2014
2	Prostaglandins AIBA 11/2023 - 12/2021
2	AerosolsIBA 09/2023 - 09/2023
2	SuspensionsIBA 08/2023 - 01/2023
2	ruxolitinibIBA 01/2023 - 01/2014
2	Janus Kinase InhibitorsIBA 01/2023 - 01/2014
2	COVID-19 VaccinesIBA 10/2022 - 01/2021
2	CholesterolIBA 01/2022 - 01/2020
2	Tetracycline (Achromycin)FDA LinkGeneric 01/2021 - 11/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 10/2020 - 01/2019
2	Lipoproteins (Lipoprotein)IBA 01/2020 - 01/2018
2	Immunomodulating AgentsIBA 10/2016 - 10/2014
2	Botulinum Toxins (Botulinum Toxin)IBA 03/2016 - 10/2012
2	Sunscreening Agents (Sunscreens)IBA 04/2014 - 05/2011

Therapy/Procedure

71	Therapeutics 05/2024 - 03/2011
15	Phototherapy (Light Therapy) 05/2024 - 12/2012
10	Biological Therapy 02/2023 - 01/2012
8	Sutures (Suture) 01/2022 - 03/2015
4	Dermatologic Surgical Procedures 01/2020 - 02/2013
3	Complementary Therapies (Alternative Medicine) 03/2024 - 02/2021
3	Photochemotherapy (Photodynamic Therapy) 11/2021 - 03/2011
3	Lasers (Laser) 06/2014 - 03/2011
2	Transjugular Intrahepatic Portasystemic Shunt 02/2024 - 05/2016
2	Contraindications 12/2023 - 12/2023
2	Critical Care (Surgical Intensive Care) 01/2021 - 12/2020
2	Aftercare (After-Treatment) 12/2019 - 06/2012
2	Tonsillectomy 10/2015 - 02/2015
2	Operative Surgical Procedures 06/2014 - 10/2012
2	Mohs Surgery (Mohs' Micrographic Surgery) 02/2014 - 07/2013